Ornella Vanoni, the Italian music star, passed away at the age of 91 on Friday, November 21, 2025. Her L’appuntamento was featured in Ocean’s Twelve, which made her music reach a global audience, which made her loved by people in various corners of the earth, not just Italy. She was famous for her sweet and melodious voice and had a career that spanned over seven decades. She breathed her last in her Milan home. According to the local outlets Corriere della Sera and AGI, the cause of death was cardiac arrest. Ornella Vanoni early life Ornella was born on 22 September 1934 in Milan, to a pharmaceutical entrepreneur. She had a very lucky upbringing, due to which she got a chance to study in Switzerland, Britain, and France. In these countries, she eventually picked up German, English, and French. Even though her family wanted her to opt for a more stable career, from a young age she felt like she was drawn to arts. Her first appearance on stage was as an actress, when she was under the mentorship of director Giorgio Strehler at Milan’s famed Piccolo Teatro. Over there she performed Brecht and other classics. Ornella Vanoni musical career She started shifting towards music in the 1950s. Earlier, she used to sing folk songs, which gave glimpses of the underbelly of Milan. Because of this, she got the nickname of “Cantante della mala” (singer of the underworld). Ornella Vanoni’s turning point The turning point in her musical career came with Senza fine in 1961, a song that is still loved and appreciated by many. Eventually she started giving out hits like Domani è un altro giorno (1971) and L’appuntamento. L’appuntamento is the Italian version of the Brazilian Sentado à beira do caminho by Erasmo Carlos and Roberto Carlos. The song was released in the 1970s and got revived when it was featured on Ocean’s Twelve. Ornella Vanoni was known for her versatility and her talent. Her legacy will forever live on through her songs.
https://www.bollywoodlife.com/viral-stories/who-is-ornella-vanoni-italian-music-star-dies-at-91-due-to-3285171/
Tag Archives: pharmaceutical
Saif Ali Khan makes major real estate move; buys commercial offices worth Rs. 30.75 crores in Mumbai
Bollywood actor Saif Ali Khan has added yet another prime asset to his real estate portfolio, this time in Mumbai’s thriving commercial district of Andheri East. According to property registration documents, the actor has purchased two office units in the Kanakia Wallstreet building for a total consideration of Rs. 30. 75 crore. Saif Ali Khan makes major real estate move; buys commercial offices worth Rs. 30. 75 crores in Mumbai The combined area of the newly acquired offices measures 5, 681 sq ft and includes six dedicated parking spaces. The seller of the property is Apiore Pharmaceutical, a US-based pharma company, as reflected in the registration filings. The deal was arranged by Volney, a real estate advisory and investor network firm. The transaction was officially registered on November 18, 2025, with a stamp duty of Rs. 1. 84 crore and a registration fee of Rs. 60, 000. Industry experts note that Andheri East has rapidly emerged as one of Mumbai’s busiest commercial corridors, attracting corporates, global enterprises, and creative firms due to its improved connectivity and infrastructure. Volney’s founder, Rohan Sheth, described the area as a market that combines accessibility with strong rental prospects, adding that it continues to draw long-term investors. Saif’s new commercial investment also places him among several high-profile names who have recently secured space in the vicinity. Elon Musk’s satellite internet company, Starlink Satellite Communications Private Limited, recently leased a 1, 294 sq. ft. office in the nearby Chandivali area for a five-year period, with total rent valued at Rs. 2. 33 crore. Additionally, the same building previously housed leased offices where Hrithik Roshan and Rakesh Roshan acquired three commercial units earlier this year for about Rs. 31 crores through HRX Digitech LLP. Beyond his latest acquisition, Saif Ali Khan is already known for his premium residential and commercial holdings across Mumbai. He currently resides in a high-end apartment in Bandra West, a property he purchased nearly a decade ago for Rs. 24 crores. Records also show that he bought a sprawling 6, 500 sq. ft. apartment in April 2012 for Rs. 23. 50 crore from Satguru Builders, further cementing his presence in the city’s luxury real estate landscape. With his latest investment, the actor continues to strengthen his position not just in cinema but also in Mumbai’s top-tier property market. Also Read: Dining with the Kapoors Trailer: Netflix brings together Bollywood’s first family for a grand tribute to Raj Kapoor BOLLYWOOD NEWS LIVE UPDATES.
https://www.bollywoodhungama.com/news/bollywood/saif-ali-khan-makes-major-real-estate-move-buys-commercial-offices-worth-rs-30-75-crores-mumbai/
Higher Open Predicted For Hong Kong Stock Market
The Hong Kong stock market has moved lower for three consecutive sessions, sinking more than 400 points, or 2.2 percent, along the way. The Hang Seng Index now rests just beneath the 18,030-point plateau, although it is likely to halt its slide on Tuesday.
The global forecast for the Asian markets is mixed, with continued profit-taking among technology stocks expected to cap any upside. European markets were up, while U.S. bourses were mostly lower; Asian markets are expected to follow the latter trend.
On Monday, the Hang Seng finished barely lower following mixed performances from financial shares, property stocks, and technology companies. For the day, the index eased 0.81 points, or 0.00 percent, to close at 18,027.71 after trading between 17,789.57 and 18,032.67.
Among the active stocks, Alibaba Group inched up 0.07 percent, while Alibaba Health Info tumbled 1.43 percent. ANTA Sports strengthened 1.09 percent, China Life Insurance gained 0.35 percent, and China Mengniu Dairy rallied 1.37 percent. Conversely, China Resources Land declined 0.74 percent, CITIC gained 0.53 percent, and both CNOOC and Xiaomi Corporation retreated 0.88 percent.
Other notable movers included Country Garden, which plunged 1.98 percent, CSPC Pharmaceutical dropping 0.47 percent, and Galaxy Entertainment tanking 1.96 percent. Hang Lung Properties sank 0.15 percent, Henderson Land jumped 1.42 percent, and Hong Kong & China Gas spiked 1.74 percent.
Additionally, Industrial and Commercial Bank of China climbed 0.88 percent, JD.com added 0.55 percent, Lenovo plummeted 2.68 percent, and Li Ning soared 1.83 percent. Meituan slumped 0.69 percent, New World Development rose 0.41 percent, Techtronic Industries advanced 0.76 percent, WuXi Biologics surged 2.07 percent, and Nongfu Spring remained unchanged.
The lead from Wall Street continues to be a dichotomy, with the major averages opening and finishing mixed. Only the Dow Jones Industrial Average closed in the green, rallying 260.88 points, or 0.67 percent, to finish at 39,411.21. Meanwhile, the NASDAQ tumbled 192.54 points, or 1.09 percent, closing at 17,496.82, and the S&P 500 fell 16.75 points, or 0.31 percent, ending at 5,447.87.
The weakness on Wall Street was driven by technology stocks, which dragged the markets lower. Shares of Nvidia Corporation, Dell Technologies, and Qualcomm all plummeted on profit-taking. Traders were also looking ahead to Friday’s Commerce Department report on personal income and spending for May, which includes inflation readings preferred by the Federal Reserve.
Oil prices gained on Monday amid optimism about demand outlook and potential supply disruptions due to tensions in the Middle East. West Texas Intermediate Crude oil futures for August rose $0.90, or 1.1 percent, to $81.63 a barrel.
*The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.*
https://www.nasdaq.com/articles/higher-open-predicted-hong-kong-stock-market
16 Eerie Series’ To Binge Watch Behind The Blanket
The first – and in my opinion, the best – season of this series is more of a crime drama, but it certainly delivers a fair dose of creepy and unsettling moments. The story revolves around a series of grisly, ritualistic murders and the investigation that follows. The narrative jumps forward and back in time, following two detectives on the case, brilliantly portrayed by Matthew McConaughey and Woody Harrelson.
**Where to watch:** Sky, Now, MAX.
This horror drama follows Atticus Black, who is accompanied by his friend Letitia and his uncle George as they travel across Jim Crow-era southern USA on a mission to find his missing father. Along their journey, they encounter horrific beings and supernatural forces, all steeped in Lovecraftian lore.
**Where to watch:** HBO Max.
You may well know *Hannibal* by now, and if you haven’t seen it, you’ve likely heard of the infamous cannibalistic character Hannibal Lecter. The series dives into the complex relationship between the forensic psychologist Lecter and FBI profiler Will Graham, showcasing how Lecter manipulates the FBI from within.
**Where to watch:** Netflix, Hulu.
With the final season on the horizon, there’s no better time to start (or rewatch) this hit series. The show follows a group of young friends and their families as their small town experiences a cascade of supernatural events. Uncovering government conspiracies and dark beings, this group soon realizes they are the town’s only hope.
**Where to watch:** Netflix.
Just in time for Halloween, this spooky miniseries is loosely based on Edgar Allan Poe’s short story of the same name, as well as various other works. The series follows a corrupt CEO of a pharmaceutical company, who struggles to come to terms with his past when horrible things begin happening to his children.
**Where to watch:** Netflix.
From the creators of *Lost*, we’re taken to a mysterious community in middle America that imprisons everyone who enters it. We watch as the residents struggle with the pressures of life in the village and seek a way out, all while surviving threats from beyond the surrounding forest.
**Where to watch:** Sky, NOW, Fubo.
This classic zombie apocalypse series follows survivors as they contend with the constant threat of the undead while navigating the dangers posed by rival groups. If you’re into zombie apocalypse shows, you’ve probably already seen it – but if not, there’s plenty of TV to catch up on here.
**Where to watch:** Disney+, Amazon Prime, Netflix.
This modern reimagining of Shirley Jackson’s novel follows a group of siblings who grew up in what would become the most famous haunted house in the country. The story focuses on their adult lives when a tragedy forces them to confront the demons of their past.
**Where to watch:** Netflix.
The series centers on a girls’ football (soccer) team en route to Seattle when their plane crashes in the Ontario wilderness. The rugged, harsh conditions begin to wear down their minds, and dark horrors start to unfold.
**Where to watch:** Paramount+, Sky, Now.
This post-apocalyptic zombie series is based on the famous video game of the same name. We follow Joel, played by Pedro Pascal, on his mission to transport Ellie, played by Bella Ramsey, across a zombie-infested wasteland in the United States.
**Where to watch:** MAX, Now, Sky.
This gothic horror centers around Riley Flynn, who returns to his isolated hometown on Crockett Island after serving four years in prison for a drunk-driving accident that resulted in a death. His return coincides with the arrival of a mysterious priest who reignites the community’s commitment to faith. However, as the community becomes divided, strange and unsettling events begin to occur.
**Where to watch:** Netflix.
While not scary all the time, *Twin Peaks* carries a haunting quality that only David Lynch can deliver. The series begins with the discovery of a corpse next to a river outside the town of Twin Peaks, Washington. From there, we’re immersed in the eerie and unsettling occurrences within the town.
**Where to watch:** Paramount+.
Series one takes us on an ill-fated voyage to the Arctic, where the crew must struggle against brutal conditions and each other. The second installment is set on the U.S. west coast during World War II, centered around Japanese folklore of bakemono, featuring a specter that torments Japanese Americans.
**Where to watch:** Amazon Prime.
https://www.buzzfeed.com/bendzialdowski/binge-worthy-tv-shows-to-watch
Review: Add ‘Bugonia’ to Yorgos Lanthimos’ resume of strange, compelling films
Any film with the name Yorgos Lanthimos attached to it means you’re in for one strange and outrageous head trip. Depending upon your sentiments regarding the filmmaker’s, ahem, unique canon—*The Lobster*, *The Favourite*, *Poor Things*, *The Killing of a Sacred Deer*, and so on—you’ll either be super hyped or devoutly disinterested when a new film of his comes out.
*Bugonia* is a different beast, and I’d bet even the filmmaker’s staunchest detractors might find a kernel or two to savor in this latest insane and insanely brilliant concoction. It promises to be one of the wildest cinematic rides of 2025. That said, *Bugonia* does stick to the Lanthimos surreal playbook, hurling out shocks, reveling in abundant weirdness, and dousing everything in dark humor.
Surprisingly, the screenplay is written by someone else: hotshot Will Tracy (*Succession*, *The Menu*). His seamless script springboards off the 2003 Korean film *Save the Planet!*. But Lanthimos doesn’t always write his films’ screenplays. In fact, some of his best works, including *Poor Things* and *The Favourite*, were penned by others.
With *Bugonia*, the loopy twists, turns, and unexpected trap-door gotchas bind together and orbit a parable that taps into an irritated, angry zeitgeist—much like the creatively inspired and culturally relevant *One Battle After Another*.
The plot presents a focused scenario—but don’t be fooled by its simplicity. An unstable “worker bee,” so to speak, named Teddy (Jesse Plemons, getting a chance to flex his acting might) and his sidekick cousin Don (Aidan Delbis) launch their crackpot alien conspiracy theories by kidnapping Michelle (Oscar-winner and frequent Lanthimos collaborator Emma Stone, delivering another awards-caliber performance), the CEO of a pharmaceutical bioengineering company.
The two buffoons shave her head, chain her in the basement of a messy remote home, and accuse her of being an alien. The shrewd, mostly composed Michelle subjects both men to an earful of strategized corporate speak as she tries to finagle her way out of this mess. Michelle is a heartless professional who sees this as a battle of wits (herself) versus dimwits (her captors). As the days inch closer to a lunar eclipse, Teddy grows increasingly antsy.
That’s about all you should know about *Bugonia*, which morphs into something far more extraordinary than its mostly confined-space thriller trappings.
The performances are exceptional across the board, including Stavros Halkias as a cop who once babysat Teddy. The fine-tuned production values, mesmerizing cinematography (filmed in extra-defined VistaVision), wardrobe choices (Plemons’ grungy clothes and Stone’s pricey couture reveal much about their characters), and the mood-appropriate score from Jerskin Fendrix (*Poor Things*) heighten and accentuate Tracy’s screenplay.
All these excellent, exacting details coexist harmoniously to produce one of Lanthimos’s best films yet—a movie of startling ingenuity that also doubles as a humorous but pointed warning to us all.
**Details:**
Rating: 4 stars out of 4
Rated: R (bloody, violent scenes including a suicide, language)
Starring: Emma Stone, Jesse Plemons, Aidan Delbis, Stavros Halkias
Director: Yorgos Lanthimos
Running Time: 1 hour, 58 minutes
When & Where: Opens in select theaters Oct. 24, expands Oct. 31
https://www.mercurynews.com/2025/10/21/review-add-bugonia-to-yorgos-lanthimos-resume-of-strange-compelling-films/
Omeros (OMER) Stock Rallies 149% on $2 Billion Novo Nordisk Deal
Omeros Corporation (NASDAQ: OMER) stock soared 149% to close at $10.19 on October 15, up $6.09 from the previous day’s close of $4.10. This dramatic surge followed the announcement of a $2.1 billion licensing and asset purchase agreement with Danish pharmaceutical giant Novo Nordisk for Omeros’ MASP-3 inhibitor drug candidate, zaltenibart (formerly OMS906).
### Significant Licensing Deal with Novo Nordisk
The deal grants Novo Nordisk exclusive worldwide rights to develop and commercialize zaltenibart, which targets rare blood and kidney disorders. Under the agreement, Omeros will receive $340 million in upfront and near-term payments, with potential milestone payments boosting the total deal value to $2.1 billion. Additionally, Omeros stands to earn royalties on future sales if zaltenibart successfully reaches the market.
Trading volume exploded to 77.9 million shares on October 15, a huge increase compared to the typical daily volume of 1.2 million shares. The stock opened the day at $11.53, hitting an intraday high of $12.77 before settling at $10.19. Over the past 52 weeks, OMER stock has traded between $0.92 and $12.87.
### Financial Position and Impact of the Deal
As of June 30, 2025, Omeros held just $28.7 million in cash and short-term investments and reported a cash burn of $58.9 million during the first half of the year. Without any current product sales and operating at a chronic loss, the company’s financial position has been precarious.
The $340 million upfront payment from Novo Nordisk is expected to bolster Omeros’ cash reserves significantly, enabling the company to pay down debts and fund operations for more than a year. Despite this, at midday on October 15, Omeros’ market capitalization was just under $700 million.
### Update on Lead Drug Candidate: Narsoplimab
While zaltenibart is a promising asset, it is not Omeros’ most advanced drug candidate. Their lead product, narsoplimab, a MASP-2 inhibitor, is currently under FDA review for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). The FDA initially rejected narsoplimab’s application in 2021, citing difficulties in estimating treatment effects and requesting additional data.
Omeros submitted further data in December 2021. The FDA set an initial target decision date of September 25, 2025, but this was later extended to December 26, 2025. This delay extends the uncertainty regarding narsoplimab’s approval and commercial potential.
Adding to the concerns, narsoplimab failed a pivotal 2023 trial testing its efficacy in treating kidney damage from an autoimmune disorder different from HSCT-TMA. Moreover, the FDA likely requested a randomized controlled trial in 2021, a study Omeros did not conduct. Instead, the company compared a small group of 28 treated patients to similar untreated patients outside the trial.
### Looking Ahead
Omeros signaled in August 2025 that a significant deal was imminent, highlighting advanced negotiations around zaltenibart. The licensing agreement with Novo Nordisk represents a critical milestone for Omeros, potentially stabilizing the company’s finances while expanding the development prospects of zaltenibart under a major pharmaceutical partner.
Investors will be closely watching the FDA’s December decision on narsoplimab, which remains pivotal to Omeros’ future commercial success.
—
*The above content is based on developments as of October 15, 2025.*
https://bitcoinethereumnews.com/tech/omeros-omer-stock-rallies-149-on-2-billion-novo-nordisk-deal/?utm_source=rss&utm_medium=rss&utm_campaign=omeros-omer-stock-rallies-149-on-2-billion-novo-nordisk-deal